Skip to main content
Premium Trial:

Request an Annual Quote

Aptus Genomics Announces $6.2 Million in Funding

NEW YORK, May 14 – Aptus Genomics added $6.2 million to its coffers in its latest round of financing, the Rockville, Maryland-based company announced Monday.

The funding came from Emerging Technology Partners, The Grosvenor Funds, and VitalBio. 

Aptus develops technology platforms to discover and analyze the function of selected families of human genes. The company, founded in June 2000, has stated it is initially concentrating its efforts on cell surface receptors. The latest round of funding will be used in R&D, staffing and general expenses, according to the company.

"Aptus’ focus on research enablement through gene discovery, qualification, and utilization will allow biotech and pharmaceutical companies, as well as Aptus’ own researchers, to accelerate drug discovery," Wei-Wu He of Emerging Technology Partners said in a statement. He is also Aptus’ Chairman of the Board.

 

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.